WO2006096515A3 - Modified transferrin fusion proteins - Google Patents

Modified transferrin fusion proteins Download PDF

Info

Publication number
WO2006096515A3
WO2006096515A3 PCT/US2006/007617 US2006007617W WO2006096515A3 WO 2006096515 A3 WO2006096515 A3 WO 2006096515A3 US 2006007617 W US2006007617 W US 2006007617W WO 2006096515 A3 WO2006096515 A3 WO 2006096515A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
moiety
transferrin fusion
diabetes
modified
Prior art date
Application number
PCT/US2006/007617
Other languages
French (fr)
Other versions
WO2006096515A2 (en
Inventor
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Original Assignee
Biorexis Pharmaceutical Corp
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp, Homayoun Sadeghi, Andrew J Turner, Christopher P Prior, David J Ballance filed Critical Biorexis Pharmaceutical Corp
Priority to JP2007558273A priority Critical patent/JP2008531059A/en
Priority to EP06736868A priority patent/EP1858546A4/en
Priority to CA002599723A priority patent/CA2599723A1/en
Publication of WO2006096515A2 publication Critical patent/WO2006096515A2/en
Publication of WO2006096515A3 publication Critical patent/WO2006096515A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Modified fusion proteins of a transferrin moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.
PCT/US2006/007617 2005-03-04 2006-03-06 Modified transferrin fusion proteins WO2006096515A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007558273A JP2008531059A (en) 2005-03-04 2006-03-06 Modified transferrin fusion protein
EP06736868A EP1858546A4 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins
CA002599723A CA2599723A1 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65814005P 2005-03-04 2005-03-04
US60/658,140 2005-03-04
US66375705P 2005-03-22 2005-03-22
US60/663,757 2005-03-22

Publications (2)

Publication Number Publication Date
WO2006096515A2 WO2006096515A2 (en) 2006-09-14
WO2006096515A3 true WO2006096515A3 (en) 2006-12-07

Family

ID=36953883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007617 WO2006096515A2 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Country Status (4)

Country Link
EP (1) EP1858546A4 (en)
JP (1) JP2008531059A (en)
CA (1) CA2599723A1 (en)
WO (1) WO2006096515A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
DK2049560T3 (en) 2006-07-13 2013-07-29 Novozymes Biopharma Dk As Process for the preparation of particles of proteinaceous material
DK2046826T3 (en) * 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusion proteins
WO2008021412A2 (en) * 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
US8822639B2 (en) 2006-12-12 2014-09-02 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
GB0711424D0 (en) * 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
EP2594583A1 (en) * 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
CA2699916A1 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
DK2513140T3 (en) 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
KR102052571B1 (en) 2010-11-30 2019-12-05 제넨테크, 인크. Low affinity blood brain barrier receptor antibodies and uses therefor
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
CN103619175B (en) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 Double acylated GLP-1 derivants
JP2014132832A (en) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd Medicament, functional food product, stabilization method of target protein, fusion protein, nucleic acid, and recombinant
US9434779B2 (en) 2012-03-19 2016-09-06 The Brigham And Women's Hospital, Inc. Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
RS57727B1 (en) 2012-03-22 2018-12-31 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
US11084860B2 (en) 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
PT3524618T (en) 2013-03-15 2023-06-06 Gladiator Biosciences Inc Gla domains as targeting agents
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
WO2014176311A1 (en) 2013-04-23 2014-10-30 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
EP3881859B1 (en) 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
CA2933335A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
JP2017518307A (en) 2014-06-02 2017-07-06 チルドレンズ メディカル センター コーポレーション Methods and compositions for immunomodulation
EP3280397A4 (en) 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
EP3313875A4 (en) 2015-06-24 2018-12-26 Board of Regents of the University of Texas System Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
JP2018525021A (en) 2015-08-27 2018-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Compositions and methods for the treatment of pain
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
WO2019014552A1 (en) * 2017-07-14 2019-01-17 University Of Southern California Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
PE20210453A1 (en) 2018-02-02 2021-03-08 Novo Nordisk As SOLID COMPOSITIONS INCLUDING A GLP-1 AGONIST, A SALT OF N- (8- (2-HYDROXIBENZOIL) AMINO) CAPRYLIC ACID AND A LUBRICANT
JP2021528437A (en) * 2018-06-21 2021-10-21 ノヴォ ノルディスク アー／エス New compounds for treating obesity
CN116600824A (en) 2020-07-10 2023-08-15 巴斯德研究所 Use of GDF11 for diagnosis and treatment of anxiety and depression
EP4165086A4 (en) * 2020-09-16 2024-07-31 Suzhou Neologics Bioscience Co Ltd Pd-l1 antibodies, fusion proteins, and uses thereof
WO2022155410A1 (en) 2021-01-15 2022-07-21 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
CN118460394B (en) * 2024-07-12 2024-09-24 通化安睿特生物制药股份有限公司 Engineering bacterium for preparing transferrin and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069193A (en) * 1996-01-11 2000-05-30 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ZA200701484B (en) * 2004-08-03 2008-07-30 Biorexis Pharmaceutical Corp Combination therapy using transferrin fusion proteins comprising GLP-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069193A (en) * 1996-01-11 2000-05-30 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALI S.A. ET AL.: "Transferrin trojan horses as a rational approach for the biological delivery of therapeutic peptide domains", J. BIOL. CHEM., vol. 274, no. 34, 20 August 1999 (1999-08-20), pages 24066 - 24073, XP008052346 *
See also references of EP1858546A4 *
XIA C.Q. ET AL.: "hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats", J PHARMACOL EXP THER, vol. 295, no. 2, 2000, pages 594 - 600, XP003004909 *
XIAO Q. ET AL.: "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo", BIOCHEMISTRY, vol. 40, no. 9, March 2001 (2001-03-01), pages 2860, XP002277645 *

Also Published As

Publication number Publication date
CA2599723A1 (en) 2006-09-14
EP1858546A4 (en) 2009-03-04
JP2008531059A (en) 2008-08-14
WO2006096515A2 (en) 2006-09-14
EP1858546A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
WO2006096515A3 (en) Modified transferrin fusion proteins
USD558816S1 (en) Eyeglass and eyeglass components
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
WO2008082669A3 (en) Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
USD581964S1 (en) Fog-resistant goggles
USD516629S1 (en) Sports mannequin
WO2006127896A3 (en) Glycopegylated factor ix
WO2004020454A3 (en) Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
ATE490969T1 (en) MODIFIED TRANSFERRIN FUSION PROTEINS
WO2008012629A3 (en) Exendin fusion proteins
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
WO2003072803A3 (en) Nanostructures containing antibody assembly units
WO2005055950A3 (en) Glycopegylated factor ix
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
WO2006066014A3 (en) Backplane design for display panels and processes for their manufacture
MX2009002999A (en) Protease resistant insulin analogues.
WO2004019872A3 (en) Oral delivery of modified transferrin fusion proteins
AU2003228364A1 (en) Field-assisted fusion bonding
WO2006020990A3 (en) Direct drive display with a multi-layer backplane and process for its manufacture
WO2007075899A8 (en) Dual agonist compounds and uses thereof
WO2009025300A1 (en) Peptide capable of binding to immunoglobulin
USD556239S1 (en) Eyeglass and eyeglass components
WO2006136932A8 (en) Lens-blocking arm-hinge for spectacle frames

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2599723

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007558273

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006736868

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU